Sinopharm Group (1099.HK) rebounds after posting an upbeat 9-month result
Sinopharm Group (1099), a pharmaceutical company, rose around 5% after the company announced that 9-month net income grew 7.8% on year to 4.96 billion yuan on operating revenue of 327.61 billion yuan, up 4.8%.
Besides, Chinese Media reported that 4 Covid-19 Vaccines of Sinopharm are conducting the Phase III clinical tests in overseas countries.
Technically, the stock posted a rebound and broke above a declining channel. Currently, the prices stand above its 20-day moving average. The relative strength index also indicates a bullish divergence signal.
The bullish readers could set a support level at HK$16.40, while resistance levels would be HK$19.00 and HK$20.40.
Source: GAIN Capital, TradingView
Besides, Chinese Media reported that 4 Covid-19 Vaccines of Sinopharm are conducting the Phase III clinical tests in overseas countries.
Technically, the stock posted a rebound and broke above a declining channel. Currently, the prices stand above its 20-day moving average. The relative strength index also indicates a bullish divergence signal.
The bullish readers could set a support level at HK$16.40, while resistance levels would be HK$19.00 and HK$20.40.
Source: GAIN Capital, TradingView
Latest market news
Today 01:26 PM
Today 01:00 PM
Yesterday 01:14 PM